OlympusTSE:7733 +2.91%83 Days Payable is 61.07 as of Mar. 2026, which is 24% below its 10-year median of 80.14. GuruFocus rates TSE:7733 with a GF Score™ of 83/100 and a GF Value™ of 円2,596.39 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Olympus ranks worse than 54.09% on this metric.
Olympus's average Accounts Payable for the
three
months ended in Mar. 2026 was 円68,613 Mil. Olympus's Cost of Goods Sold for the
three
months ended in Mar. 2026 was 円102,522 Mil.
Hence, Olympus's Days Payable for the
three
months ended in Mar. 2026 was 61.07.
The historical rank and industry rank for Olympus's Days Payable or its related term are showing as below:
TSE:7733'
s Days Payable Range Over the Past 10 Years
Min: 64.17 Med: 80.14 Max: 101.84
Current: 64.17
During the past 13 years, Olympus's highest Days Payable was 101.84. The lowest was 64.17. And the median was 80.14.
TSE:7733's Days Payable is ranked worse than 54.09% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TSE:7733: 64.17
Olympus's Days Payable
declined
from Mar. 2025 (67.68) to Mar. 2026 (61.07).
It may suggest that Olympusaccelerated paying its suppliers.
Olympus Days Payable Related Terms
Olympus Days Payable Historical Data
* Premium members only.
The historical data trend for Olympus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7733 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Olympus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olympus Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Days Payable distribution charts can be found below:
* The bar in red indicates where Olympus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Olympus's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olympus (TSE:7733) has a Days Payable of 61.07 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Olympus and its competitors. This is 24% below median its historical median of 80.14. Over the past decade, Olympus' Days Payable has ranged from 64.17 to 101.84. According to the industry distribution chart, Olympus ranks #430 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 54.1%.
Is Olympus' Days Payable too high?
Olympus' current Days Payable of 61.07 is 24% below median its 10-year median of 80.14. Over the past 10 years, this metric has ranged from a low of 64.17 to a high of 101.84. The Medical Devices & Instruments industry median Days Payable is 68.07. Olympus' value of 61.07 is 10.3% below this industry median. Based on the distribution chart, Olympus ranks #430 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Olympus has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #430 out of 795 companies for Days Payable. This places Olympus in the lower half of its industry. The industry median Days Payable is 68.07. Olympus' value of 61.07 is 10.3% below this benchmark. Historically, Olympus' own Days Payable has ranged from 64.17 to 101.84 over the past decade. While the company's 10-year median is 80.14 vs. the industry median of 68.07, Olympus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olympus's current Days Payable of 61.07 is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Olympus and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olympus's current Days Payable is 61.07, which is 24% below median its own 10-year median of 80.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (TSE:7733) is currently considered Significantly Undervalued. The stock's GF Value™ is 円2,596.39, compared to a current price of 円1,768.00 — trading 31.9% below its estimated fair value. The current Days Payable is 61.07, which is 24% below median its 10-year median of 80.14 and 10.3% below the Medical Devices & Instruments industry median of 68.07. Olympus' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Olympus (TSE:7733), the current Days Payable is 61.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Olympus (TSE:7733) Overvalued in 2026?
Based on GuruFocus' analysis, Olympus stock appears to be undervalued.
The current stock price of 円1,768.00 is trading 31.9% below its estimated GF Value™ of 円2,596.39.
GuruFocus considers Olympus to be Significantly Undervalued.
Key valuation signals for TSE:7733:
Days Payable: 61.07 (24% below median its 10-year median of 80.14)
GF Value™: 円2,596.39 vs. price of 円1,768.00 (31.9% below fair value)
Industry Position: 10.3% below the Medical Devices & Instruments median (#430 of 795)
No single metric tells the full story. See the TSE:7733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
83GF Score
Get the complete analysis for TSE:7733
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7733 has been successfully added to your 
